BioSyent Pharma Launches New RepaGyn® Hormone-Free Vaginal Suppositories
May 21 2014 - 8:00AM
Marketwired
BioSyent Pharma Launches New RepaGyn® Hormone-Free Vaginal
Suppositories
TORONTO, ONTARIO--(Marketwired - May 21, 2014) - BioSyent Inc.
("BioSyent") (TSX-VENTURE:RX) today announced that its subsidiary
BioSyent Pharma Inc. has commenced the Canadian launch of new
RepaGyn® Hormone-Free Vaginal Suppositories.
RepaGyn® (sodium hyaluronate) is an innovative vaginal
suppository recommended for the healing of the vaginal mucosa and
the treatment of vaginal dryness caused by menopause, stress and
chemotherapy. It is also recommended in situations where tissue
repair is required after invasive vaginal surgeries and biopsy
procedures. RepaGyn® vaginal suppositories can be used with or
without local hormone therapy.
RepaGyn® is formulated with sodium hyaluronate, a naturally
occurring compound, and offers a hormone-free treatment alternative
proven to deliver symptom relief, restoration of pH balance, and
tissue repair in one ovule. RepaGyn® has established clinical
evidence of both efficacy and symptom relief and has been
recommended by doctors and successfully used by women in several
European countries including Italy, France, Belgium, Switzerland,
Denmark and Poland for over 10 years under the brand names
Cicatridine®, Cicatridina®, Cikatridina®, and Repadina®.
"The launch of RepaGyn® is an important milestone in the
development of the BioSyent Pharma business," commented René
Goehrum, CEO of BioSyent. "The product itself is consistent with
our strategy of sourcing unique products that address unmet medical
needs for the Canadian healthcare market, and represents a further
broadening of our portfolio. The patient population that can
benefit from RepaGyn® is significant."
RepaGyn® is approved by Health Canada and was in-licensed by
BioSyent Pharma for exclusive marketing and distribution in Canada
from FARMA-DERMA s.r.l., Italy in October of 2013. Shipments to
wholesalers and pharmacies will commence in June 2014.
To learn more about RepaGyn®, please visit the website
www.RepaGyn.ca.
For a direct market quote (15 minutes delay) for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol
"RX", BioSyent is a profitable growth oriented specialty
pharmaceutical company which searches the globe to in-license or
acquire innovative pharmaceutical products that have been
successfully developed, are safe and effective, and have a proven
track record of improving the lives of patients and supporting the
healthcare professionals that treat them.
Once a product of interest has been found, BioSyent then
acquires the exclusive rights to the product and manages it through
the Canadian governmental regulatory approval process. Once
approved, BioSyent markets the product throughout Canada.
At the date of this press release the Company had 13,776,195
shares issued and outstanding.
This press release may contain information or statements that
are forward-looking. The contents herein represent our judgment, as
at the release date, and are subject to risks and uncertainties
that may cause actual results or outcomes to be materially
different from the forward-looking information or statements.
Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
The TSX Venture
Exchange assumes no responsibility for the accuracy of this release
and neither approves nor disapproves of the same.
BioSyent Inc.Mr. Rene C. GoehrumPresident and CEO(905)
206-0013investors@biosyent.comwww.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Aug 2023 to Aug 2024